Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0BQ8M
|
|||
| Former ID |
DIB015035
|
|||
| Drug Name |
CY-208243
|
|||
| Synonyms |
Indolophenanthridine; CY 208-243; 100999-26-6; CY-208-243; 4,6,6a,7,8,12b-Hexahydro-7-methylindolo(4,3-ab)-phenanthridine; Indolo(4,3-ab)phenanthridine, 4,6,6a,7,8,12b-hexahydro-7-methyl-, trans-(-)-; (6aR,12bR)-7-methyl-4,6,6a,7,8,12b-hexahydroindolo[4,3-ab]phenanthridine; Tocris-1249; AC1L1ODE; Biomol-NT_000032; AC1Q1IN1; CHEMBL313737; BPBio1_001225; SCHEMBL9364562; DTXSID9042598; CHEBI:93399; MolPort-003-983-825; HMS3267H13; ZINC26501186; AKOS024456489; API0009347; NCGC00025078-01; NCGC00025078-02; LS-183405
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Pain [ICD-11: MG30-MG3Z] | Discontinued in Phase 2 | [1] | |
| Company |
Novartis AG
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H18N2
|
|||
| Canonical SMILES |
CN1CC2=CC=CC=C2C3C1CC4=CNC5=CC=CC3=C45
|
|||
| InChI |
1S/C19H18N2/c1-21-11-12-5-2-3-6-14(12)19-15-7-4-8-16-18(15)13(10-20-16)9-17(19)21/h2-8,10,17,19-20H,9,11H2,1H3/t17-,19-/m1/s1
|
|||
| InChIKey |
WRNKIDLXXXIELU-IEBWSBKVSA-N
|
|||
| CAS Number |
CAS 100999-26-6
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:93399
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Dopamine D1 receptor (D1R) | Target Info | Agonist | [2], [3] |
| Neuron-specific vesicular protein calcyon (CALY) | Target Info | Activator | [3] | |
| KEGG Pathway | Calcium signaling pathway | |||
| cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| Gap junction | ||||
| Dopaminergic synapse | ||||
| Parkinson's disease | ||||
| Cocaine addiction | ||||
| Amphetamine addiction | ||||
| Morphine addiction | ||||
| Alcoholism | ||||
| Panther Pathway | Dopamine receptor mediated signaling pathway | |||
| Pathwhiz Pathway | Dopamine Activation of Neurological Reward System | |||
| Reactome | Dopamine receptors | |||
| G alpha (s) signalling events | ||||
| WikiPathways | Hypothetical Network for Drug Addiction | |||
| Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| Genes and (Common) Pathways Underlying Drug Addiction | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Decrease of behavioral and biochemical denervation supersensitivity of rat striatum by nigral transplants. Neuroscience. 1991;44(1):75-83. | |||
| REF 2 | The D-1 dopamine receptor partial agonist, CY 208-243, exhibits antiparkinsonian activity in the MPTP-treated marmoset. Eur J Pharmacol. 1988 Nov 1;156(2):197-206. | |||
| REF 3 | Dopamine D1 receptor agonists induce penile erections in rats. Eur J Pharmacol. 2003 Jan 26;460(1):71-4. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.